At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
Botulinum Toxin Type A (Azzalure) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range
In Brief
A Phase 3 clinical trial evaluating Botulinum Toxin Type A (Azzalure) and Restylane ranges for Aging. Completed, enrolled 60 participants across 5 sites in 3 countries.
Detailed Summary
The aim of this study is to assess subjects' satisfaction linked to the pan facial management of rejuvenation with injections of Azzalure® and Restylane® fillers. This will be an open, multi-centre study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesFrance, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedFeb 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedFeb 8, 2012
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.4 years ago
Interventions
Botulinum Toxin Type A (Azzalure)drug
Powder for solution for injection
Restylane rangesdevice
Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)